K Kian Ang

K Kian Ang

University of Texas-MD Anderson Cancer Center, Houston, Texas | Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA | ...

KOL Resume for K Kian Ang  (radiotherapy, malignant neoplasm, malignant neoplasms, radiotherapy, malignant, radiotherapy neoplasm, after, for, followup, examination, followup examination, cancer, neoplasm)


University of Texas-MD Anderson Cancer Center, Houston, Texas

MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.


David I. Rosenthal, Diana Bell, and Kian K. Ang, The University of Texas MD Anderson Cancer Center, Houston, TX; Paul M. Harari, University of Wisconsin, Madison, WI; Jordi Giralt, Hospital Vall d'Hebron, Barcelona, Spain; David Raben, University of Colorado School of Medicine, Aurora, CO; Joyce Liu, Merck Serono, Beijing, People's Republic of China; Jeltje Schulten, Merck KGaA, Darmstadt, Germany; and James A. Bonner, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL.

The University of Texas MD Anderson Cancer Center Department of Radiation Oncology Houston Texas


MD Anderson Cancer Center, Houston, TX


University of Texas MD Anderson Cancer Center Houston Texas

MD Anderson Cancer Center, Houston, TX, USA


MD Anderson Cancer Center, Houston, Texas

Hector MacLean Distinguished Professor of Cancer Research, Department of Radiation Oncology, University of North Carolina Lineberger, Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina

Emeritus Professor and Consultant, Department of Radiation Oncology, Mayo Clinic College of Medicine and Mayo Clinic, Scottsdale, Arizona


Authors' Affiliations: Departments of Radiation Oncology and Head and Neck Surgery, The University of Texas MD Anderson Cancer Center; Bobby R. Alford Department of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston; and Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, Texas

University of Chicago, Chicago, IL

LDS Hospital, Salt Lake City, UT

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Maimonides Cancer Center, Brooklyn, NY


University of Texas M.D. Anderson Cancer Center, Houston, TX

Radiation Oncology Department, MD Anderson Cancer Center, Houston, USA


Moffitt Cancer Center, Tampa, FL

Image-Guided Therapy Center

Institute of Cancer Research, Chester Beatty Laboratories, London, United Kingdom

Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

University of California, San Francisco, San Francisco


Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Box 97, 1515 Holcombe Blvd., Houston, TX 77030; Fax: 713‐563‐2366.

Radiation Therapy Oncology Group Headquarters and Statistical Center and the American College of Radiology, Philadelphia, PA

Maimonides Medical Center, NY

From the Jefferson Medical College and Kimmel Cancer Center of Thomas Jefferson University


Prominent publications by K Kian Ang

KOL Index score: 21017

BACKGROUND: Previous results from our phase 3 randomised trial showed that adding cetuximab to primary radiotherapy increased overall survival in patients with locoregionally advanced squamous-cell carcinoma of the head and neck (LASCCHN) at 3 years. Here we report the 5-year survival data, and investigate the relation between cetuximab-induced rash and survival.

METHODS: Patients with LASCCHN of the oropharynx, hypopharynx, or larynx with measurable disease were randomly allocated in a ...

Known for Patients Cetuximab |  Locoregionally Advanced Head |  Antibodies Monoclonal Antibodies |  Year Survival |  Neck Cancer
KOL Index score: 18817

PURPOSE: Surgery is the primary treatment for adenoid cystic carcinomas arising from major and minor salivary glands of the head and neck. However, local recurrence is frequent because of the infiltrative growth pattern and perineural spread associated with these tumors. At UTMDACC, we have had a longstanding policy of using postoperative radiotherapy to reduce the risk of local recurrence and to avoid the need for radical surgery; this 30-year retrospective study analyzes the results of ...

Known for Positive Margins |  Nerve Invasion |  Adenoid Cystic |  Postoperative Radiotherapy |  Neck Surgery
KOL Index score: 18505

PURPOSE: The optimal fractionation schedule for radiotherapy of head and neck cancer has been controversial. The objective of this randomized trial was to test the efficacy of hyperfractionation and two types of accelerated fractionation individually against standard fractionation.

METHODS AND MATERIALS: Patients with locally advanced head and neck cancer were randomly assigned to receive radiotherapy delivered with: 1) standard fractionation at 2 Gy/fraction/day, 5 days/week, to 70 ...

Known for Standard Fractionation |  Rtog 9003 |  Neck Squamous |  5 Week |  Female Head
KOL Index score: 18459

PURPOSE: We conducted a retrospective evaluation of the IMCL-9815 study to examine the association of human papillomavirus (HPV) and p16 protein expression status with outcomes in patients with oropharyngeal carcinoma (OPC) receiving radiotherapy (RT) plus cetuximab or RT alone.

PATIENTS AND METHODS: In the IMCL-9815 study, patients were randomly allocated to receive RT plus weekly cetuximab or RT alone. A subpopulation of patients with p16-evaluable OPC was retrospectively evaluated on ...

Known for Human Papillomavirus |  P16 Status |  Cetuximab Patients |  Phase Iii |  Squamous Cell
KOL Index score: 17297

PURPOSE: Epithelial-mesenchymal transition (EMT) has been associated with metastatic spread and EGF receptor (EGFR) inhibitor resistance. We developed and validated a robust 76-gene EMT signature using gene expression profiles from four platforms using non-small cell lung carcinoma (NSCLC) cell lines and patients treated in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) study.

EXPERIMENTAL DESIGN: We conducted an integrated gene expression, ...

Known for Egfr Inhibitor Resistance |  Pi3k Inhibitors |  Therapeutic Target |  Gene Signature |  Nsclc Emt
KOL Index score: 17024

BACKGROUND: Radiation dermatitis occurs to some degree in most patients receiving radiotherapy, with or without chemotherapy. Patients with squamous cell carcinoma of the head and neck (SCCHN) who receive radiotherapy in combination with epidermal growth factor receptor (EGFR) inhibitors, such as cetuximab, may develop a characteristic acne-like rash in addition to dermatitis.

DESIGN: An advisory board of 11 experienced radiation oncologists, medical oncologists and dermatologists ...

Known for Egfr Inhibitors |  Radiation Dermatitis |  Squamous Cell Carcinoma |  Monoclonal Antibodies |  Neck Scchn
KOL Index score: 16500

BACKGROUND: The gold standard endpoint in randomised trials of locally advanced head and neck squamous-cell carcinoma (HNSCC) is overall survival. Our objective was to study whether duration of locoregional control or event-free survival (EFS) could be considered as surrogate endpoints to estimate the effect of radiotherapy and chemotherapy on overall survival. This would allow a reduction in the duration and cost of the development of new treatments.

METHODS: Individual patient data ...

Known for Surrogate Endpoints |  Individual Patient Data |  Locally Advanced Head |  Locoregional Control |  Efs Survival
KOL Index score: 15468

Epithelial-mesenchymal transition (EMT) is associated with characteristics of breast cancer stem cells, including chemoresistance and radioresistance. However, it is unclear whether EMT itself or specific EMT regulators play causal roles in these properties. Here we identify an EMT-inducing transcription factor, zinc finger E-box binding homeobox 1 (ZEB1), as a regulator of radiosensitivity and DNA damage response. Radioresistant subpopulations of breast cancer cells derived from ...

Known for Dna Damage |  Emt Radioresistance |  Ataxia Telangiectasia |  Zeb1 Promotes |  Protein 1
KOL Index score: 15390

BACKGROUND: In the current study the authors assessed the antitumor activity (including response rate, duration of response, and survival) and toxicity profile (including anorexia, fatigue, emesis, and peripheral neuropathy) of a combination of paclitaxel, ifosfamide, and carboplatin (TIC) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). The trial hypothesis was that the TIC therapeutic index would be as high as that of paclitaxel, ...

Known for Squamous Cell |  Metastatic Head |  Paclitaxel Ifosfamide |  Carboplatin Patients |  Median Duration
KOL Index score: 15201

PURPOSE: To report results of a randomized phase II trial (Radiation Therapy Oncology Group RTOG-0234) examining concurrent chemoradiotherapy and cetuximab in the postoperative treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) with high-risk pathologic features.

PATIENTS AND METHODS: Eligibility required pathologic stage III to IV SCCHN with gross total resection showing positive margins and/or extracapsular nodal extension and/or two or more nodal ...

Known for Postoperative Chemoradiotherapy |  Squamous Cell |  Cetuximab Patients |  Head Neck |  Cisplatin Arm
KOL Index score: 15168

BACKGROUND: Sinonasal neuroendocrine tumors are rare malignancies that are represented by a spectrum of histologies, including esthesioneuroblastoma (ENB), sinonasal undifferentiated carcinoma (SNUC), neuroendocrine carcinoma (NEC), and small cell carcinoma (SmCC). The authors reviewed their institutional experience to determine whether sinonasal neuroendocrine tumors of different histologies have distinct clinical characteristics that warrant individualized treatment ...

Known for Enb Patients |  Sinonasal Malignancies |  Neuroendocrine Differentiation |  5 Years |  Undifferentiated Carcinoma
KOL Index score: 15062

PURPOSE: In this randomized, phase III study, quality of life (QoL) was assessed in patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) after high-dose radiotherapy alone or in combination with cetuximab.

PATIENTS AND METHODS: Patients with stage III or IV nonmetastatic and measurable squamous cell carcinoma of the oropharynx, hypopharynx, or larynx were eligible. QoL was assessed using the European Organisation for Research and Treatment of Cancer ...

Known for Cetuximab Patients |  Life Qol |  Monoclonal Antibodies |  Locoregional Control |  Receptors Head
KOL Index score: 14720

PURPOSE: Combining cisplatin or cetuximab with radiation improves overall survival (OS) of patients with stage III or IV head and neck carcinoma (HNC). Cetuximab plus platinum regimens also increase OS in metastatic HNC. The Radiation Therapy Oncology Group launched a phase III trial to test the hypothesis that adding cetuximab to the radiation-cisplatin platform improves progression-free survival (PFS).

PATIENTS AND METHODS: Eligible patients with stage III or IV HNC were randomly ...

Known for Neck Carcinoma |  Stage Iii |  Cisplatin Cetuximab |  Pfs Patients |  Female Head
KOL Index score: 14447

BACKGROUND: This retrospective study assesses the outcomes and patterns of failure in patients with squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site treated with combined surgery and postoperative radiotherapy.

METHODS: One hundred thirty-six patients with squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary source were treated postoperatively with radiotherapy at the University of Texas M. D. Anderson Cancer Center ...

Known for Primary Site |  Squamous Cell |  Carcinoma Metastatic |  Postoperative Radiation |  Cervical Lymph


K Kian Ang: Influence Statistics

Sample of concepts for which K Kian Ang is among the top experts in the world.
Concept World rank
ac480 radiosensitivity #1
hypopharynx hyperfractionated radiotherapy #1
pretreatment qol survival #1
day mfd schedule #1
ahfxs 16 fraction #1
opscc rtog #1
hyperfractionated radiotherapy patients #1
iseganan oral #1
animals 44 #1
0522 patients #1
treatment small 4 #1
ionizing receptor ac480 #1
carcinoma nasal cavity #1
mice fractionated irradiations #1
ice ectatic capillaries #1
reduction serous acini #1
prophylaxis protection #1
quality ctv delineation #1
split outcome #1
accelerated regimens #1
lower lrc survival #1
radiotherapy survival rates #1
pai1 fibrin zymography #1
doses 110 #1
extracapsular nodal disease #1
nasal cavity septum #1
t2b hyperfractionation #1
p05 sfx #1
imcl9815 study association #1
igrt adaptive replans #1
response jejunal mucosa #1
flavopiridol lyth #1
major radiation failure #1
unpartnered whites lrc #1
structures imrt #1
feasibility studies head #1
areas graft loss #1
radiation daily dose #1
pretreatment level apoptosis #1
3 xerostomia grade #1
repair kinetics chart #1
41 25 #1
hyperfractionation fractionation #1
cytotoxic drugs radiation #1
ethmoid sinus carcinomas #1
radiation injury kidney #1
sc236 50 microm #1
radiotherapy locoregional control #1
pni pai1 #1
nonmelanoma skin carcinomas #1

Key People For Radiation Therapy

Top KOLs in the world
Carlos A Perez
radiation therapy uterine cervix tumor control
James D Cox
radiation therapy lung cancer small cell
Ahmedin M Jemal
united states breast cancer addis ababa
Walter John Curran
radiation therapy brain metastases lung cancer
Ritsuko R Komaki
lung cancer radiation therapy small cell
Thomas F Pajak
radiation therapy neck cancer late effects

K Kian Ang:Expert Impact

Concepts for whichK Kian Anghas direct influence:Radiation therapy,  Spinal cord,  Head neck,  Neck cancer,  Squamous cell,  Radiation therapy oncology,  Neck neoplasms humans,  Cell carcinoma.

K Kian Ang:KOL impact

Concepts related to the work of other authors for whichfor which K Kian Ang has influence:Squamous cell,  Neck cancer,  Radiation therapy,  Nasopharyngeal carcinoma,  Human papillomavirus,  Oral cavity,  Local control.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

University of Texas-MD Anderson Cancer Center, Houston, Texas | Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA | Department of Experimental Radiation Oncology, The University of Texas MD Anderson

FREE Custom List